|
2/2022
vol. 24
abstract:
Varia
Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology and Polish Society for Colposcopy and Cervical Pathophysiology on prophylactic vaccinations against infections with human papillomaviruses in Poland
Andrzej Nowakowski
1, 2
,
Agnieszka Mastalerz-Migas
9
,
- Cervical Cancer Prevention Clinic, Central Coordinating Centre for Cervical Cancer Screening Program, Department of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- Obstetrics and Gynaecology Ward, District Specialist Hospital, Siedlce, Poland
- Department of Endocrine Gynaecology, Collegium Medicum of the Jagiellonian University, Cracow, Poland; President of the Polish Society for Colposcopy and Cervical Pathophysiology, Vice President of the Polish Society of Gynaecologists and Obstetricians, Chairman of the Cervical Pathology, Colposcopy and Cytology Section of the Polish Society of Gynaecologists and Obstetricians, Member of the Board of the Polish Society of Oncological Gynaecology (PTGO) and Chairman of the Section for the prevention and treatment of cervical cancer at PTGO
- Clinical Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland; Polish Vaccinology Society
- Department of Oncological Gynaecology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; National Consultant Oncological Gynaecology
- Faculty of Medical Sciences and Health Sciences, Kazimierz Pulaski University of Technology and Humanities, Radom, Poland
- Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland; National Consultant in the field of Paediatrics, Polish Paediatric Society
- Medical University in Lublin, Lublin, Poland; Polish Society of Oncological Gynaecology
- Chair and Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland; National Consultant in Family Medicine
- Department of Social Medicine and Public Health, Warsaw Medical University, Warsaw, Poland; Polish Society of Family Medicine
- School of Public Health, Medical Centre of Postgraduate Education, Warsaw, Poland; National Consultant in Public Health
- Chair and Department of Obstetrics, Women’s Diseases and Oncological Gynaecology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland; President of the Polish Society of Oncological Gynaecology
- First Department of Gynaecology and Obstetrics, Medical University of Lodz, Lodz, Poland; President Polish Society of Gynaecologists and Obstetricians
- Department of Gynaecological Oncology, Pomeranian Hospitals, Gdynia, Poland; Vice President of the Polish Society for Colposcopy and Cervical Pathophysiology
- Division of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland
- Observation and Infectious Diseases Department of the Specialist Mother and Child Healthcare Group in Poznan, Chair and Department of Health Prophylaxis, Medical University of Poznan, Poznan, Poland; Polish Society of Vaccinology
Family Medicine & Primary Care Review 2022; 24(2): 177–184
Online publish date: 2022/06/30
PlumX metrics:
Several hundred million people are infected with genital genotypes of the human papillomavirus (HPV) annually in the world. The infections transmitted mainly through sexual routes are usually asymptomatic, but can lead to the development of cervical, vulvar, vaginal, anal, penile cancers, some head and neck cancers and genital warts (condylomas). The fraction of HPV-related cancers ranges from nearly 100% in the case of cervical cancer to several/over a dozen percent in the case of other cancers and diseases. There are no effective drugs against HPV, but prophylactic HPV vaccines are available free of charge in immunisation programmes in many countries around the world. In Poland, HPV vaccinations have so far been executed out of pocket or in free-of-charge, local-governmental prevention programs, but the vaccination coverage of the target population does not exceed 10%. Starting in November 2021, one of the vaccines has been available with a 50% reimbursement, and work is underway to reimburse the next ones. The National Oncology Strategy assumes the implementation of the HPV immunisation programmes and vaccination of 60% of the teen population by 2028. Three prophylactic HPV vaccines are registered. All of them are safe and their effectiveness in the prevention of diseases caused by vaccine genotypes is almost 100% provided that full post-vaccination immunity is obtained before contact with the virus. Girls aged 11–13 are the priority target cohort for HPV vaccination in Poland. The implementation of routine, free-of-charge HPV immunisation in the Preventive Immunisation Program (PIP) for all adolescents should be pursued. Persons over the age of 13 may also benefit from HPV vaccination and should be vaccinated according to product specifications. In addition to free access under the PIP, the key element for the success of the implementation of HPV vaccinations in Poland will be the education of medical personnel and parents of adolescents to be vaccinated.
keywords:
alphapapillomavirus, uterine cervical neoplasms, vaccines
|
|
